Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
Mohraz M, Vahdat K, Ghamari SH, Abbasi-Kangevari M, Ghasemi E, Ghabdian Y, Rezaei N, Pouya MA, Abdoli A, Malekpour MR, Koohgir K, Saeedi Moghaddam S, Tabarsi P, Moghadami M, Khorvash F, Khodashahi R, Salehi M, Hosseini H.
Mohraz M, et al.
BMJ. 2023 Sep 21;382:e070464. doi: 10.1136/bmj-2023-070464.
BMJ. 2023.
PMID: 37734752
Free PMC article.
Clinical Trial.
SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. ...
SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injectio …